Dry eye disease can also manifest as a result of systemic disease.
Sjogren's syndrome is an autoimmune disorder which affects the entire body, but initially include typical symptoms of dry eyes and dry mouth. Ninety percent of those diagnosed with Sjogren's syndrome are female. It sometimes occurs in the presence of Lupus, scleroderma, and rheumatoid arthritis.
An early diagnosis of Sjögren’s syndrome is key component to establishing a treatment plan for managing this major autoimmune disease. There is currently no cure for sjogren's and statistics show 1 in 10 dry eye patients have this illness.
Our diagnostic test, Sjö, aids in the early detection of Sjögren’s syndrome. This test is administered and available to bill to insurance. Preventative care, diagnosis, treatment and management of Sjögren’s syndrome are crucial as it can manifest systemically with multiple complications. With previous test options, Sjögren’s syndrome was not typically diagnosed until an average of about 4.7 years after onset. At this time, damage to the glands has already occurred.
Sjö is an in-office diagnostic test that allows health care professionals to detect Sjögren's syndrome earlier than ever before by testing not only the 4 traditional biomarkers, but also 3 new, novel, proprietary biomarkers that are specific to the presence of Sjögren’s syndrome. Sjö has 89% cumulative sensitivity and 78.2% cumulative specificity in comparison to 40-60% through previous tests available. This means that it is much more accurate than its previous counterparts.
Click on the image to learn more about Sjo, Baush & Lomb's diagnostic test for Sjogren's syndrome.